SCHEMBL4870568

SCHEMBL4870568

Cc1oc2nc(S(C)(=O)=O)nc(NCc3ccccn3)c2c1-c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 3/20 0.43
KCNH2 Q12809 5/20 0.41
MAPK14 Q16539 2/20 0.41
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
PTGS2 P35354 1/20 0.38
JAK2 O60674 2/20 0.37
PTK2 Q05397 1/20 0.37
PIP4K2C Q8TBX8 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
CDK5 Q00535 1/20 0.37
PDE5A O76074 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SCN9A Q15858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5246200 0.92 KCNH2 (0.46) KCNA5KCNH2JAK2PIP4K2CCCNE1
SCHEMBL4866797 0.83 KCNH2 (0.52) KCNA5KCNH2MAPK14MAPK13MAPK12
SCHEMBL4868763 0.75 KCNA5 (0.49) KCNA5KCNH2JAK2CCNE1CDK2
SCHEMBL4870563 0.75 SLC11A2 (0.34) PTGS2LMNASMN1; SMN2
SCHEMBL4865901 0.74 KCNH2 (0.49) KCNA5KCNH2JAK2PTK2PIP4K2C
SCHEMBL4871028 0.73 AURKA (0.61) KCNA5KCNH2LMNATSHRHTT
SCHEMBL2369196 0.65 SMN1; SMN2 (0.42) KCNA5KCNH2MAPK14MAPK13MAPK12
SCHEMBL3386735 0.65 TNF (0.59) KCNA5KCNH2JAK2PIP4K2CCCNE1
SCHEMBL2369248 0.65 KCNA5 (0.45) KCNA5KCNH2MAPK14MAPK13MAPK12
SCHEMBL2368544 0.64 KCNA5 (0.44) KCNA5KCNH2MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US disclosed
EP-1758909-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2007-03-07 EP disclosed
WO-2005121149-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2005-12-22 WO disclosed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors KCNH3, HCN4, KCNH2 KCNA5 6/4885KCNH2 3/4885MAPK14 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.